Reperfusion injury in ST-segment elevation myocardial infarction: the final frontier

Area of Science:

• Cardiology
• Cellular Biology
• Pathophysiology

Background:

• ST-segment elevation myocardial infarction (STEMI) is a leading cause of death globally.
• Reperfusion injury (RI) exacerbates myocardial damage and infarct size after restoring blood flow.
• Approximately 50% of final infarct size is attributed to RI, which is difficult to treat.

Purpose of the Study:

• To propose a hypothesis explaining the failure of reperfusion injury prevention strategies.
• To elucidate the phases of myocardial damage following ischemia and reperfusion.
• To identify key factors contributing to the clinical ineffectiveness of RI preventive therapies.

Main Methods:

• Review of experimental studies on reperfusion injury.
• Hypothesis formulation based on myocardial damage phases (reversible ischemia, irreversible ischemia, necrosis).
• Analysis of preventive strategies' efficacy in experimental versus clinical settings.

Main Results:

• Myocardial damage progresses through reversible, irreversible, and necrosis phases.
• Preventive therapies for RI fail as they cannot rescue cells in the irreversible ischemia phase.
• Strategies may postpone cell death or shift it to apoptosis, but fail to salvage irreversibly damaged myocardium.

Conclusions:

• Failure to salvage myocardium in the irreversible ischemia phase underlies the ineffectiveness of RI preventive strategies.
• Understanding the shift from necrosis to apoptosis is crucial for explaining clinical trial failures.
• Early reperfusion, before irreversible damage occurs, remains the optimal strategy to minimize RI-related myocardial damage.